PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

不适用 进行中（已停止招募） NCT04089059

摘要

This is a prospective, open- label, single arm, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System in NYHA Class III Heart Failure Patients compared to a Performance Goal (PG).

Efficacy 6 Month Incidence of HF Related Hospitalizations (HFH) or All-cause Mortality

6 months · Events Per Patient Per 6 Months

Safety: Freedom From Device/System Related Complication

6 months · Proportion of patients without a DSRC

Safety: Freedom From Pressure Sensor Failure

6 months · Proportion of patients without a PSF

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• Implantation of a Permanent Interatrial Shunt to Reduce Left Atrial Filling Pressures Foll — samir kapadia
• Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant — University of Utah
• Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure — Yale University
• Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
• Crome/Cobalt Respiration Study — Medtronic Cardiac Rhythm and Heart Failure

全部试验